Adage Capital Partners’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Adage Capital Partners’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-600,000	Closed	-$14.2M	–	786
2019 Q3	$14.2M	Buy	600,000 +200,000	+50%	+$5.93M	0.03%	447
2019 Q2	$12M	Buy	400,000 +50,000	+14%	+$1.15M	0.03%	496
2019 Q1	$7.84M	Buy	350,000 +150,000	+75%	+$3.22M	0.02%	558
2018 Q4	$3.64M	Buy	+200,000	New	+$3.14M	0.01%	633
2017 Q4	–	Sell	-68,000	Closed	-$993K	–	774
2017 Q3	$993K	Sell	68,000 -47,000	-41%	-$710K	﹤0.01%	691
2017 Q2	$2.15M	Sell	115,000 -26,000	-18%	-$587K	0.01%	662
2017 Q1	$3M	Sell	141,000 -34,000	-19%	-$650K	0.01%	646
2016 Q4	$2.66M	Buy	+175,000	New	+$2.38M	0.01%	641

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners's RARX Position: Q4 2019 in Review

Adage Capital Partners sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 600,000 shares — an estimated $14.2M sold.

Adage Capital Partners first reported a position in RARX in Q4 2016 and held it in 8 quarters. The position peaked at $14.2M in Q3 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Adage Capital Partners reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Adage Capital Partners sold 600,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $14.2M.
Adage Capital Partners first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 8 quarters.
Adage Capital Partners's Ra Pharmaceuticals, Inc. Common Stock position peaked at $14.2M in Q3 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Adage Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.